Tempus ECG-AF vs IM007
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tempus ECG-AF is designed for early identification of patients at risk of developing new-onset atrial fibrillation within 12 months, utilizing 12-lead ECG analysis. In contrast, IM007 is a comprehensive remote monitoring platform for patients with existing cardiac implantable electronic devices, focusing on data aggregation, workflow automation, and reducing false alerts, including those related to AF from CIEDs. While both operate in cardiology and address aspects of atrial fibrillation, their distinct target populations and core functionalities make them complementary rather than directly competitive.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Tempus ECG-AF is an FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. IM007 is an FDA-cleared, AI-powered, cloud-based platform for remote cardiac monitoring that aggregates data from all cardiac implantable electronic devices (CIEDs) to streamline workflows, reduce false alerts, and improve patient outcomes in cardiology and heart failure management.
Tempus ECG-AF is intended for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. IM007 is designed for patients with cardiac implantable electronic devices (CIEDs) for remote monitoring and management.
Tempus ECG-AF analyzes 12-lead ECG recordings from FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems. IM007 aggregates and analyzes data from various cardiac implantable electronic devices (CIEDs), including those from Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort.
Tempus ECG-AF focuses on detecting signs associated with new onset Atrial Fibrillation (AF) within 12 months. IM007 features AI-Driven Alert Management to reduce false positives (e.g., 79% for ILR ECG Analyzer, 85% for AF alerts) and includes SignalHF, an FDA-cleared predictive AI for heart failure hospitalization risk.
CMS reimbursement is available for Tempus ECG-AF, with CPT codes 0764T and 0765T assigned to APC 5734, at a Medicare rate of $128.90, effective January 1, 2025. While IM007 mentions smart workflow automation for billing and is reimbursed in many countries, the provided information does not specify particular CPT codes or Medicare rates for its services.